ARTICLE | Clinical News
Tracleer bosentan: Phase II/III; marketed to treat pulmonary arterial hypertension (PAH)
March 10, 2003 8:00 AM UTC
ATLN started the double-blind, placebo-controlled international Phase II/III BUILD-2 trial of 125 mg of Tracleer in 138 patients. ...